Shin Nippon Biomedical Laboratories, Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, company now expects Revenue of JPY 25,000 million compared to JPY 24,000 million which is previously announced, Operating profit to be JPY 5,460 million compared to JPY 5,260 million, Profit attributable to owners of parent to be JPY 5,310 million compared to JPY 7,000 million and Profit per share to be JPY 127.54 compared to JPY 168.13 as previously expected.
Shin Nippon Biomedical Laboratories, Ltd.
Equities
2395
JP3379950003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,502 JPY | +1.49% | +5.55% | -11.54% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.54% | 397M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- 2395 Stock
- News Shin Nippon Biomedical Laboratories, Ltd.
- Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023